Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac)

Journal article

AbstractAs the first dose of Gam-COVID-Vac, is currently used as a single dose vaccine in some countries, we investigated the immunogenicity of this at 4 weeks (327 naïve individuals). 88.7% seroconverted, with significantly lower seroconversion rates in those over 60 years (p = 0.004) and significantly lower than previously seen with AZD1222 (p = 0.018). 82.6% developed ACE2 receptor blocking antibodies, although levels were significantly lower than following natural infection (p = 0.0009) and a single dose of AZD1222 (p < 0.0001). Similar titres of antibodies were observed to the receptor binding domain of WT, B.1.1.7 and B.1.617.2 compared to AZD1222, while the levels for B.1.351 were significantly higher (p = 0.006) for Gam-COVID-Vac. 30% developed ex vivo IFNγ ELISpot responses (significantly lower than AZD1222), and high frequency of CD107a expressing T cells along with memory B cell responses. Although single dose of Gam-COVID-Vac was highly immunogenic, administration of a second dose is likely to be beneficial.

Authors: Jeewandara, C; Fernando, S; Pushpakumara, PD; Ramu, ST; Kamaladasa, A

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Nature Research
• Journal: Scientific Reports
• Volume: 12
• Issue: 1
• Pages: 1727-1727
• Article number: 1727
• Publication date: 2022-02-02
• DOI: 10.1038/s41598-022-05788-6
• EISSN: 2045-2322
• ISSN: 2045-2322
• Language: English
• Keywords: Immunology; Virology; Biology; Coronavirus disease 2019 (COVID-19); Betacoronavirus; Disease; Medicine; Infectious disease (medical specialty); Internal medicine; Immune system; Outbreak; 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Coronavirus Infections